A mutation that may protect metabolism. What did a million-person study find?

What did researchers find?

Some people are born with extremely rare genetic variants that can alter the way their bodies manage energy. In a new study published in Nature, researchers analyzed genetic data from more than one million people and identified a particularly interesting example of such a mechanism.

The gene in question is FNIP1, which is involved in regulating cellular energy metabolism. People carrying ultra-rare variants that reduce the function of one copy of this gene showed a more favorable metabolic profile.

The observed differences included:

• Carriers of FNIP1 variants had a lower triglyceride-to-HDL ratio, which the researchers used as one marker of metabolic state.
• They also had lower triglyceride and ApoB levels, indicating a more favorable lipid profile.
• They showed less liver fat and a healthier distribution of body fat.
• Their data indicated better glycemic control.
• Most notably, they had approximately 60% lower odds of a composite outcome that included coronary artery disease, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and liver cirrhosis.

This does not mean that switching off FNIP1 is already a proven treatment for metabolic disease. However, the findings suggest that FNIP1 may represent a promising biological target for future therapies.

Study details

The study combined a very large human genetic analysis with laboratory experiments in human cells and animal models. This allowed the researchers not only to identify an interesting genetic association, but also to investigate possible mechanisms behind it.

• Publication title: FNIP1 variants are associated with favourable metabolism in 1 million humans
• Authors: George Hindy, Rene C. Adam, Olukayode Sosina, and colleagues.
• Publication date: August 5, 2026.
• Journal: Nature.
• DOI: 10.1038/s41586-026-10864-2
• PMID: 42557317
• Full publication: Nature
• PubMed: PMID 42557317
• Study type: Multi-cohort rare coding variant association analysis based on exome sequencing, supplemented with phenotypic analyses and mechanistic experiments in cells and mice.
• Population: 1,032,116 participants across 11 cohorts from the Americas, Europe, and Asia, including people with diverse genetic ancestries.
• Primary analyzed marker: The triglyceride-to-HDL cholesterol ratio (TG:HDL), used as a marker associated with energy metabolism.
• Genetic analysis: Researchers searched for rare protein-coding variants associated with differences in TG:HDL and other metabolic traits.
• Key finding: They identified 59 independently associated genes. Particular attention was given to ultra-rare protein-truncating variants in FNIP1, with an allele frequency of approximately 0.01%.
• Mechanistic validation: The FNIP1 pathway was investigated in primary human hepatocytes and in mouse models.

The enormous sample size made it possible to detect variants so rare that their health effects would be extremely difficult to study in much smaller genetic datasets.

---

FNIP1 and metabolism

FNIP1 encodes folliculin-interacting protein 1, a protein that works together with proteins including FLCN, or folliculin. This pathway is involved in regulating how cells respond to the availability of energy and nutrients.

One of its functions can be simplified as limiting energy expenditure and promoting energy storage.

From an evolutionary perspective, such a mechanism may have been highly useful. In environments where periods of food abundance alternated with scarcity, efficient energy storage could improve the chances of survival.

Modern conditions are very different. Constant access to energy-dense food combined with low physical activity in parts of the population means that the same biological mechanisms may contribute to excess energy storage, obesity, fatty liver disease, and metabolic dysfunction.

This is why partial loss of FNIP1 function is particularly interesting: it may shift the body’s balance away from energy storage and toward greater energy utilization.

---

What did the human data show?

The researchers did not begin their analysis with FNIP1. They first analyzed exome data from more than one million people and searched for rare genetic variants associated with the TG:HDL ratio.

This approach identified 59 genes independently associated with this metabolic marker. Many of them were particularly active in the liver and adipose tissue, two organs that play central roles in energy metabolism.

FNIP1 stood out because of the broader metabolic profile associated with its loss-of-function variants.

People carrying ultra-rare variants that reduced the function of one copy of the gene showed several favorable characteristics:

• They had lower triglycerides and lower ApoB, indicating a more favorable lipid profile.
• They had less fat stored in the liver, an important marker associated with metabolic dysfunction.
• They showed a healthier distribution of adipose tissue, suggesting differences not only in the amount of fat but also in where it was stored.
• They had more favorable glycemic measures.
• They had approximately 60% lower odds of the composite cardiometabolic outcome that included coronary artery disease, type 2 diabetes, MASLD, and liver cirrhosis.

However, it is important to distinguish the composite outcome from the individual diseases. Reductions in coronary artery disease and cirrhosis analyzed separately did not reach statistical significance, in part because the relevant FNIP1 variants were so rare that the number of carriers was small.

---

Experiments in cells and mice

A genetic association alone does not explain why a variant would alter metabolism. The researchers therefore performed additional mechanistic experiments.

In primary human hepatocytes, reducing FNIP1 activity changed the expression of genes involved in processes including lysosomal activity and lipid breakdown.

The researchers also studied mice fed a diet high in fat and fructose.

Disrupting the FNIP1-FLCN pathway in the animals' livers was associated with several effects:

• The animals were more resistant to diet-induced weight gain, suggesting a change in how excess energy was handled.
• They developed less fat accumulation in the liver.
• The mice showed better insulin sensitivity.

There was, however, an important difference between humans and mice. In the animal models, stronger effects required simultaneous interference with FNIP1 and the related FNIP2 gene, or disruption of FLCN. In human hepatocytes, reducing FNIP1 alone was sufficient to produce some of the metabolic changes.

This highlights why results from animal experiments cannot automatically be translated directly to humans.

---

What could this mean for future therapies?

Human genetics can help identify potential drug targets. If people who naturally have reduced activity of a particular gene throughout life also show a favorable health profile, this may provide a clue that partially inhibiting the same pathway with a drug could be beneficial.

The FNIP1 findings are particularly interesting because the evidence does not end with a genetic association.

The study provides three complementary layers of evidence:

1. Human genetics shows that reduced FNIP1 function is associated with a more favorable metabolic profile.
2. Experiments in human cells show that reducing FNIP1 activity affects pathways involved in lipid metabolism and breakdown.
3. Animal experiments suggest that interfering with the pathway may reduce some consequences of a diet that promotes metabolic dysfunction.

This is still an early stage in the development of any potential therapy. The study does not establish a clinically proven FNIP1-blocking treatment that can currently be used to improve metabolism.

The broader genetic analysis is also noteworthy. Of the 59 genes identified in the study, 23 encode targets of drugs that are already approved or undergoing clinical development. This illustrates how the study of rare human genetic variants can help uncover biological pathways with potential relevance for drug discovery.

---

Key limitations

Despite the enormous number of participants, the findings related to FNIP1 need to be interpreted carefully. Studies of ultra-rare genetic variants have a built-in paradox: the overall population can exceed one million people while the number of individuals carrying the particular variant of interest remains small.

The main limitations include:

• The loss-of-function FNIP1 variants were extremely rare, with an allele frequency of approximately 0.01%. As a result, some analyses of individual diseases were based on relatively few carriers.
• The approximately 60% reduction applied to the odds of a composite cardiometabolic outcome, not necessarily to every disease analyzed separately. Individual results for coronary artery disease and cirrhosis did not reach statistical significance.
• A natural, lifelong partial reduction in gene function may not produce the same effects as pharmacologically inhibiting FNIP1 beginning in adulthood.
• The mouse experiments did not perfectly reproduce what was observed in human cells. These species differences could make translation into a therapy more difficult.
• The study identifies a potentially interesting therapeutic target, but does not establish the long-term safety of inhibiting FNIP1 in humans.

The key conclusion is therefore not that scientists have found a gene that can simply be switched off to prevent metabolic disease. The more important finding is that a natural genetic experiment in humans points to a biological pathway whose lifelong partial disruption is associated with an unusually favorable metabolic profile.

---

Sources

• Hindy G, Adam RC, Sosina O, et al. FNIP1 variants are associated with favourable metabolism in 1 million humans. Nature. 2026;657:703–712. Nature
• PubMed – PMID 42557317